Eric Sellal

BioSellal

The ‘One Health’ concept: How veterinary diagnostics is aiding COVID-19 detection

Since the start of the pandemic, the team at biotechnology company BioSellal has been applying its expertise in animal health diagnostics to help improve the detection of COVID-19 and its variants. In this video, Eric Sellal, CEO of BioSellal, shares insight into the company’s work developing and validating real-time PCR and ELISA methods for the reliable antibody detection.



LIKE 3


Eric Sellal
COVID-19: Infectious disease

Eric Sellal

Biography

In 1990, Eric Sellal founded... More
Follow Eric

Eric Sellal

BioSellal

In 1990, Eric Sellal founded the company LSI, which he managed until 2012. In February 2014, he created BioSellal, a French biotechnology company specializing in the development, production, and commercialization of real-time ELISA and PCR reagents for animal infectiology. During this period, he and his team developed tools for the application of NGS technology to animal health and marketed the first PCR and ELISA kits in September 2015. In May 2020 and in the context of the current health crisis, BioSellal diversified its activities and mobilized to develop a range of PCR reagents for medical biology to contribute to the detection of SARS-CoV-2 and its variant strains. Today, the company offers more than 100 kits in its catalog.